-
Something wrong with this record ?
Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial
A. Landi, D. Heg, E. Frigoli, P. Vranckx, S. Windecker, P. Siegrist, G. Cayla, A. Włodarczak, S. Cook, I. Gómez-Blázquez, Y. Feld, P. Seung-Jung, M. Mates, C. Lotan, S. Gunasekaran, M. Nanasato, R. Das, H. Kelbæk, E. Teiger, J. Escaned, Y....
Language English Country United States
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- MeSH
- Stroke * etiology prevention & control MeSH
- Myocardial Infarction * complications MeSH
- Platelet Aggregation Inhibitors MeSH
- Drug Therapy, Combination MeSH
- Percutaneous Coronary Intervention * adverse effects methods MeSH
- Hemorrhage chemically induced MeSH
- Humans MeSH
- Drug-Eluting Stents * adverse effects MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Clinical outcomes and treatment selection after completing the randomized phase of modern trials, investigating antiplatelet therapy (APT) after percutaneous coronary intervention (PCI), are unknown. OBJECTIVES: The authors sought to investigate cumulative 15-month and 12-to-15-month outcomes after PCI during routine care in the MASTER DAPT trial. METHODS: The MASTER DAPT trial randomized 4,579 high bleeding risk patients to abbreviated (n = 2,295) or standard (n = 2,284) APT regimens. Coprimary outcomes were net adverse clinical outcomes (NACE) (all-cause death, myocardial infarction, stroke, and BARC 3 or 5 bleeding); major adverse cardiac and cerebral events (MACCE) (all-cause death, myocardial infarction, and stroke); and BARC type 2, 3, or 5 bleeding. RESULTS: At 15 months, prior allocation to a standard APT regimen was associated with greater use of intensified APT; NACE and MACCE did not differ between abbreviated vs standard APT (HR: 0.92 [95% CI: 0.76-1.12]; P = 0.399 and HR: 0.94 [95% CI: 0.76-1.17]; P = 0.579; respectively), as during the routine care period (HR: 0.81 [95% CI: 0.50-1.30]; P = 0.387 and HR: 0.74 [95% CI: 0.43-1.26]; P = 0.268; respectively). BARC 2, 3, or 5 was lower with abbreviated APT at 15 months (HR: 0.68 [95% CI: 0.56-0.83]; P = 0.0001) and did not differ during the routine care period. The treatment effects during routine care were consistent with those observed within 12 months after PCI. CONCLUSIONS: At 15 months, NACE and MACCE did not differ in the 2 study groups, whereas the risk of major or clinically relevant nonmajor bleeding remained lower with abbreviated compared with standard APT. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).
Cardiology Department Rambam Healthcare Campus Haifa Israel
Cardiothoracic Centre Freeman Hospital Newcastle United Kingdom
CTU Bern University of Bern Bern Switzerland
Department of Biomedical Sciences University of Italian Switzerland Lugano Switzerland
Department of Cardiology Apollo Main Hospital Chennai India
Department of Cardiology Bern University Hospital Bern Switzerland
Department of Cardiology Fribourg Hospital Cantonal Villars Sur Glâne Fribourg Switzerland
Department of Cardiology Hospital Universitario 12 de Octubre Madrid Spain
Department of Cardiology Institute for Cardiovascular Disease Sremaska Kamenica Serbia
Department of Cardiology Maasstad Hospital Rotterdam the Netherlands
Department of Cardiology Miedziowe Centrum Zdrowia Lubin Poland
Department of Cardiology Na Homolce Hospital Cardiovascular Center Prague Czech Republic
Department of Cardiology Nimes University Hospital University of Montpellier Nimes France
Department of Cardiology Sakakibara Heart Institute Tokyo Japan
Department of Cardiology University Hospital Henri Mondor Créteil France
Department of Cardiology Zealand University Hospital Roskilde Denmark
Department of Cardiovascular Medicine Gifu Heart Center Gifu Japan
Department of Internal Medicine Sungkyunkwan University School of Medicine Seoul Republic of Korea
Faculty of Medicine and Life Sciences Hasselt University Hasselt Belgium
Heart Center Hadassah Medical Center Faculty of Medicine Hebrew University Jerusalem Israel
HerzZentrum Hirslanden Zurich Switzerland
Sorbonne University ACTION group Groupe Hospitalier Pitie Salpetriere Hospital Paris France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010461
- 003
- CZ-PrNML
- 005
- 20230801132436.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jcin.2023.01.366 $2 doi
- 035 __
- $a (PubMed)37045500
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Landi, Antonio $u Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: https://twitter.com/antoniolandii
- 245 10
- $a Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial / $c A. Landi, D. Heg, E. Frigoli, P. Vranckx, S. Windecker, P. Siegrist, G. Cayla, A. Włodarczak, S. Cook, I. Gómez-Blázquez, Y. Feld, P. Seung-Jung, M. Mates, C. Lotan, S. Gunasekaran, M. Nanasato, R. Das, H. Kelbæk, E. Teiger, J. Escaned, Y. Ishibashi, G. Montalescot, H. Matsuo, D. Debeljacki, PC. Smits, M. Valgimigli, MASTER DAPT Investigators
- 520 9_
- $a BACKGROUND: Clinical outcomes and treatment selection after completing the randomized phase of modern trials, investigating antiplatelet therapy (APT) after percutaneous coronary intervention (PCI), are unknown. OBJECTIVES: The authors sought to investigate cumulative 15-month and 12-to-15-month outcomes after PCI during routine care in the MASTER DAPT trial. METHODS: The MASTER DAPT trial randomized 4,579 high bleeding risk patients to abbreviated (n = 2,295) or standard (n = 2,284) APT regimens. Coprimary outcomes were net adverse clinical outcomes (NACE) (all-cause death, myocardial infarction, stroke, and BARC 3 or 5 bleeding); major adverse cardiac and cerebral events (MACCE) (all-cause death, myocardial infarction, and stroke); and BARC type 2, 3, or 5 bleeding. RESULTS: At 15 months, prior allocation to a standard APT regimen was associated with greater use of intensified APT; NACE and MACCE did not differ between abbreviated vs standard APT (HR: 0.92 [95% CI: 0.76-1.12]; P = 0.399 and HR: 0.94 [95% CI: 0.76-1.17]; P = 0.579; respectively), as during the routine care period (HR: 0.81 [95% CI: 0.50-1.30]; P = 0.387 and HR: 0.74 [95% CI: 0.43-1.26]; P = 0.268; respectively). BARC 2, 3, or 5 was lower with abbreviated APT at 15 months (HR: 0.68 [95% CI: 0.56-0.83]; P = 0.0001) and did not differ during the routine care period. The treatment effects during routine care were consistent with those observed within 12 months after PCI. CONCLUSIONS: At 15 months, NACE and MACCE did not differ in the 2 study groups, whereas the risk of major or clinically relevant nonmajor bleeding remained lower with abbreviated compared with standard APT. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 12
- $a stenty uvolňující léky $x škodlivé účinky $7 D054855
- 650 _2
- $a krvácení $x chemicky indukované $7 D006470
- 650 12
- $a infarkt myokardu $x komplikace $7 D009203
- 650 12
- $a koronární angioplastika $x škodlivé účinky $x metody $7 D062645
- 650 _2
- $a inhibitory agregace trombocytů $7 D010975
- 650 12
- $a cévní mozková příhoda $x etiologie $x prevence a kontrola $7 D020521
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Heg, Dik $u CTU Bern, University of Bern, Bern, Switzerland
- 700 1_
- $a Frigoli, Enrico $u Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Università della Svizzera Italiana, Lugano, Switzerland; CTU Bern, University of Bern, Bern, Switzerland
- 700 1_
- $a Vranckx, Pascal $u Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
- 700 1_
- $a Windecker, Stephan $u Department of Cardiology, Bern University Hospital, Bern, Switzerland
- 700 1_
- $a Siegrist, Patrick $u HerzZentrum Hirslanden Zurich, Switzerland
- 700 1_
- $a Cayla, Guillaume $u Department of Cardiology, Nimes University Hospital, University of Montpellier, Nimes, France
- 700 1_
- $a Włodarczak, Adrian $u Department of Cardiology, Miedziowe Centrum Zdrowia, Lubin, Poland
- 700 1_
- $a Cook, Stephane $u Department of Cardiology, Fribourg Hospital Cantonal, Villars-Sur-Glâne, Fribourg, Switzerland
- 700 1_
- $a Gómez-Blázquez, Iván $u Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain
- 700 1_
- $a Feld, Yair $u Cardiology Department, Rambam Healthcare Campus, Haifa, Israel
- 700 1_
- $a Seung-Jung, Park $u Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- 700 1_
- $a Mates, Martin $u Department of Cardiology, Na Homolce Hospital Cardiovascular Center, Prague, Czech Republic
- 700 1_
- $a Lotan, Chaim $u Heart Center, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel
- 700 1_
- $a Gunasekaran, Sengottuvelu $u Department of Cardiology, Apollo Main Hospital, Chennai, India
- 700 1_
- $a Nanasato, Mamoru $u Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan
- 700 1_
- $a Das, Rajiv $u Cardiothoracic Centre, Freeman Hospital, Newcastle, United Kingdom
- 700 1_
- $a Kelbæk, Henning $u Department of Cardiology, Zealand University Hospital, Roskilde, Denmark
- 700 1_
- $a Teiger, Emmanuel $u Department of Cardiology, University Hospital Henri Mondor, Créteil, France
- 700 1_
- $a Escaned, Javier $u Department of Cardiology, Hospital Clínico San Carlos IDISSC and Universidad Complutense de Madrid, Madrid, Spain
- 700 1_
- $a Ishibashi, Yuki $u Department of Internal Medicine, Division of Cardiology, St. Marianna University School of Medicine, Kawasaki, Japan
- 700 1_
- $a Montalescot, Gilles $u Sorbonne University, ACTION group, Groupe Hospitalier Pitie-Salpetriere Hospital, Paris, France
- 700 1_
- $a Matsuo, Hitoshi $u Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
- 700 1_
- $a Debeljacki, Dragan $u Department of Cardiology, Institute for Cardiovascular Disease, Sremaska Kamenica, Serbia
- 700 1_
- $a Smits, Pieter C $u Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands
- 700 1_
- $a Valgimigli, Marco $u Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Università della Svizzera Italiana, Lugano, Switzerland; Department of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland. Electronic address: marco.valgimigli@eoc.ch
- 710 2_
- $a MASTER DAPT Investigators
- 773 0_
- $w MED00186218 $t JACC. Cardiovascular interventions $x 1876-7605 $g Roč. 16, č. 7 (2023), s. 798-812
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37045500 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132433 $b ABA008
- 999 __
- $a ok $b bmc $g 1963091 $s 1196726
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 16 $c 7 $d 798-812 $e 2023Apr10 $i 1876-7605 $m JACC. Cardiovascular interventions $n JACC Cardiovasc Interv $x MED00186218
- LZP __
- $a Pubmed-20230718
